MS progression and immune cells after bone marrow transplant and other therapies
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at how well different treatments, including bone marrow transplant, alemtuzumab, ocrelizumab, and ofatumumab, work for people with relapsing-remitting MS who have active disease. It will help doctors understand which therapy might slow disease progression best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have relapsing-remitting MS (RRMS) as diagnosed by current standards
- You have had at least 2 relapses in the past year, or 1 relapse plus new MRI lesions in the past year
- You are being considered for one of these treatments: bone marrow transplant, alemtuzumab, ocrelizumab, or ofatumumab
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a donor bone marrow transplant (allogeneic hematopoietic cell transplantation) can stop or slow the progression of primary progressive multiple sclerosis. It is for people with worsening symptoms who have not responded to other treatments.
This trial tests if using your own stem cells can stop multiple sclerosis that keeps getting worse despite treatment. You would first receive a medication to reset your immune system, then get your stem cells back to help rebuild it.
This early-phase study tests a stem cell transplant procedure for people with multiple sclerosis whose usual MS medicines have not worked or can’t be tolerated. The goal is to see if this approach can help control MS activity and progression, while checking for safety.
This study follows adults with relapsing multiple sclerosis who are switching from ocrelizumab to ofatumumab (two similar MS medications) to see how their immune system proteins (immunoglobulins) change during the switch. It may help doctors understand if this change improves your immune health while treating MS.
This early-stage trial tests a combination treatment—a CD20 antibody (which targets certain immune cells) paired with NK042 cell injection (a type of immune cell therapy)—for people with multiple sclerosis. The goal is to evaluate whether this combination is safe and may help slow disease progression.
This trial tests a new cell therapy called SYS6020 for people with multiple sclerosis that has not improved with standard treatments. The goal is to see if it can slow or stop the disease and improve symptoms.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.